Substituted aromatic compounds and related method for the treatment of fibrosis
The present invention relates to compounds of: or a pharmaceutically acceptable salt thereof, wherein A is C 5 alkyl, C 6 alkyl, C 5 alkenyl, C 6 alkenyl, C(O)—(CH 2 ) n —CH 3 or CH(OH)—(CH 2 ) n —CH 3 wherein n is 3 or 4; R 1 is H, F or OH; R 2 is C 5 alkyl, C 6 alkyl, C 5 alkenyl, C 6 alkenyl, C(O)—(CH 2 ) n —CH 3 or CH(OH)—(CH 2 ) n —CH 3 wherein n is 3 or 4; R 3 is H, F, OH or CH 2 Ph; R 4 is H, F or OH; Q is 1) (CH 2 ) m C(O)OH wherein m is 1 or 2, 2) CH(CH 3 )C(O)OH, 3) C(CH 3 ) 2 C(O)OH, 4) CH(F)—C(O)OH, 5) CF 2 —C(O)OH, or 6) C(O)—C(O)OH; and compositions comprising the same and the method using the same for the prevention or treatment of various fibrotic diseases and conditions in subjects, including pulmonary fibrosis, liver fibrosis, skin fibrosis, renal fibrosis, pancreas fibrosis, systemic sclerosis, cardiac fibrosis or macular degeneration.
1. A kit for preventing and/or slowing progression of and/or treating fibrotic disease in a subject in need thereof, wherein said kit comprises (a) a pharmaceutically acceptable salt of a compound of the formula:
wherein
A is straight C 5 alkyl, straight C 6 alkyl, C 5 alkenyl, C 6 alkenyl, C(O)—(CH 2 ) n —CH 3 or CH(OH)—(CH 2 ) n —CH 3 wherein n is 3 or 4;
R 1 is H, F or OH;
R 2 is straight C 5 alkyl, straight C 6 alkyl, C 5 alkenyl, C 6 alkenyl, C(O)—(CH 2 ) n —CH 3 or CH(OH)—(CH 2 ) n —CH 3 wherein n is 3 or 4;
R 3 is H, F, OH or CH 2 Ph;
R 4 is H, F or OH;
Q is
1) (CH 2 ) m C(O)OH wherein m is 1 or 2,
2) CH(CH 3 )C(O)OH,
3) C(CH 3 ) 2 C(O)OH,
4) CH(F)—C(O)OH,
5) CF 2 —C(O)OH, or
6) C(O)—C(O)OH;
and wherein the pharmaceutically acceptable salt of said compound is sodium, potassium, lithium, ammonium, calcium, magnesium, manganese, zinc, iron, or copper; and
(b) instructions for administering a therapeutically effective amount of the pharmaceutically acceptable salt to the subject suffering from said fibrotic disease.
2. The kit of claim 1 , wherein the fibrotic disease is pulmonary fibrosis, liver fibrosis, skin fibrosis, renal fibrosis, pancreas fibrosis, systemic sclerosis, cardiac fibrosis or macular degeneration.
3. The kit of claim 1 , comprising instructions for administering between about 1 to about 50 mg/kg of the pharmaceutically acceptable salt daily and orally to the subject who is a human.
4. The kit of claim 1 , comprising instructions for administering between about 0.01 to about 10% (w/w) of the pharmaceutically acceptable salt daily and topically to the subject who is a human, and wherein the fibrotic disease is skin fibrosis.
5. The kit of claim 1 , wherein the fibrotic disease is pulmonary fibrosis.
6. The kit of claim 1 , wherein the fibrotic disease is liver fibrosis.
7. The kit of claim 1 , wherein the fibrotic disease is skin fibrosis.
8. The kit of claim 1 , wherein the fibrotic disease is cardiac fibrosis.
9. The kit of claim 1 , wherein the fibrotic disease is renal fibrosis.
10. The kit of claim 4 , wherein the concentration of the pharmaceutically acceptable salt is between about 0.1 to about 5% (w/w).
11. The kit of claim 10 , wherein the concentration of the pharmaceutically acceptable salt is between about 1 to about 5% (w/w).
12. The kit of claim 1 , wherein the pharmaceutically acceptable salt of said compound is sodium.
13. The kit of claim 1 , wherein said pharmaceutically acceptable salt is a pharmaceutically acceptable salt of one of the following compounds:
14. The kit of claim 1 , wherein Q is (CH 2 )C(O)OH.
15. The kit of claim 1 , wherein A and R 2 are straight C 5 alkyl.
16. The kit of claim 1 , wherein R 1 is H and R 3 is H.
17. The kit of claim 1 , wherein R 4 is H or OH.
18. The kit of claim 13 , wherein said pharmaceutically acceptable salt is a pharmaceutically acceptable salt of the following compound
19. The kit of claim 13 , wherein said pharmaceutically acceptable salt is a pharmaceutically acceptable salt of the following compound